Please assess the completion status of the following clinical trial:

Trial Title: PsA Treatment With hOKT3γ1 (Ala-Ala)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of psoriatic arthritis. Participants do not need to have concurrent psoriasis to participate in the study;~* Active inflammation in 3 or more joints;~* Currently receiving ongoing therapy with methotrexate or azathioprine; and~* Willing to use acceptable forms of contraception.~Exclusion Criteria:~* Active infection with HIV, hepatitis C virus, or hepatitis B virus;~* Uncompensated heart failure or a recent myocardial infarction (heart attack) within the 6 months prior to study entry;~* Certain other serious illnesses or cancers;~* Participation in another clinical trial within the 6 weeks prior to study entry; or~* Pregnant or breastfeeding.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- hOKT3gamma1 (Ala-Ala) (Type: EXPERIMENTAL): Escalating dose of hOKT3gamma1 (Ala-Ala) given intravenously over 5 days of each 28 day cycle
- Placebo (Type: PLACEBO_COMPARATOR): Intravenous dose of placebo given over 5 days of each 28 day cycle

Based on this trial design, predict the completion outcome and termination type (if applicable).